Literature DB >> 31016539

New treatment-induced adverse effects we need to learn as modern hepatologists.

Yoshiyuki Ueno1.   

Abstract

Keywords:  Immune check point inhibitor; Liver toxicity; Molecular targetting drug; PD-1; PD-L1

Mesh：

Substances：

Year:  2019        PMID： 31016539     DOI： 10.1007/s12072-019-09947-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


× No keyword cloud information.
  14 in total

Review 1.  Immune checkpoint blockade for the treatment of human hepatocellular carcinoma.

Authors:  Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatol Res       Date:  2018-06-06       Impact factor: 4.288

2.  Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.

Authors:  Eleonora De Martin; Jean-Marie Michot; Barbara Papouin; Stéphane Champiat; Christine Mateus; Olivier Lambotte; Bruno Roche; Teresa Maria Antonini; Audrey Coilly; Salim Laghouati; Caroline Robert; Aurélien Marabelle; Catherine Guettier; Didier Samuel
Journal:  J Hepatol       Date:  2018-02-08       Impact factor: 25.083

3.  Combination Cancer Immunotherapy in Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-01-31       Impact factor: 11.740

4.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

5.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

6.  Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.

Authors:  Brandon M Huffman; Lisa A Kottschade; Patrick S Kamath; Svetomir N Markovic
Journal:  Am J Clin Oncol       Date:  2018-08       Impact factor: 2.339

7.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

Review 8.  Liver Toxicity with Cancer Checkpoint Inhibitor Therapy.

Authors:  Brian A Nadeau; Leslie A Fecher; Scott R Owens; Nataliya Razumilava
Journal:  Semin Liver Dis       Date:  2018-10-24       Impact factor: 6.115

9.  Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.

Authors:  Masatoshi Kudo; Etsuro Hatano; Shinichi Ohkawa; Hirofumi Fujii; Akihide Masumoto; Junji Furuse; Yoshiyuki Wada; Hiroshi Ishii; Shuntaro Obi; Shuichi Kaneko; Seiji Kawazoe; Osamu Yokosuka; Masafumi Ikeda; Katsuaki Ukai; Sojiro Morita; Akihito Tsuji; Toshihiro Kudo; Mitsuo Shimada; Yukio Osaki; Ryosuke Tateishi; Gen Sugiyama; Paolo Benjamin Abada; Ling Yang; Takuji Okusaka; Andrew Xiuxuan Zhu
Journal:  J Gastroenterol       Date:  2016-08-22       Impact factor: 7.527

10.  Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.

Authors:  Kenji Ikeda; Masatoshi Kudo; Seiji Kawazoe; Yukio Osaki; Masafumi Ikeda; Takuji Okusaka; Toshiyuki Tamai; Takuya Suzuki; Takashi Hisai; Seiichi Hayato; Kiwamu Okita; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2016-10-04       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.